Results 121 to 130 of about 149 (146)

Cisplatin and Carboplatin

2021
Platinum-based agents belong to alkylating antineoplastic agents. They are the backbone of most chemotherapeutic regimens in many cancer types, including testicular cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, bladder cancer, and head and neck cancer.
Michelle N. Johnson, Lili Zhang
openaire   +2 more sources

Elasticity of Cisplatin-Bound DNA Reveals the Degree of Cisplatin Binding

Physical Review Letters, 2008
Cisplatin was incidentally discovered to suppress cell division and became one of the most successful antitumor drugs. It is therapeutically active upon binding to DNA and locally kinking it. We demonstrate that after a bimodal modeling, the degree of platination of a single DNA molecule can be consistently and reliably estimated from elasticity ...
Kyoung J. Lee, Seok Cheol Hong, Jin Sung Park, Sergei Obukhov, Sergei Obukhov, Nam-Kyung Lee, Nam-Kyung Lee, Albert Johner, Ju Yong Hyon   +8 more
openaire   +5 more sources

Cisplatin-Induced Hemolysis

New England Journal of Medicine, 1980
CISPLATIN (cis-diamminedichloroplatinum) has been tested extensively against various solid tumors and has become commercially available.
J Fitzpatrick, E P Getaz, A Dozier, S Beckley   +3 more
openaire   +3 more sources

Adriamycin and cisplatin for hepatoblastoma

Cancer, 1985
Four consecutive infants and children with hepatoblastomas were treated with a combination of Adriamycin (doxorubicin) and cisplatin. Three patients had unresectable tumors and in each there was a dramatic decrease in tumor size and serum alpha-fetoprotein (AFP) levels.
Ronald W. Cooke, Arnold J. Altman, Donald W. Hight, H. Thomas Robinson, James H. Foster, John J. Quinn   +5 more
openaire   +3 more sources

Is Cisplatin a Human Carcinogen?

JNCI Journal of the National Cancer Institute, 1992
Traditionally, cisplatin has not been regarded among chemotherapeutic drugs as a carcinogenic risk to humans because it is not a classical alkylating agent. A review of recently published experimental data indicates that cisplatin is mutagenic, clastogenic, capable of inducing cell transformation, able to act as an initiator in classical mouse skin ...
openaire   +3 more sources

Cisplatin overdosage.

Journal of Clinical Oncology, 1992
I M, Pike, M H, Arbus
openaire   +4 more sources

Mechanisms of resistance to cisplatin [PDF]

, 1991
A number of changes have been detected in cisplatin-resistant cells, some of which are likely to be directly involved in the mechanism of resistance. The four most cited mechanisms are reduced accumulation, increased glutathione, increased metallothionein, and enhanced DNA repair.
openaire   +2 more sources

CARBOPLATIN OR CISPLATIN?

The Lancet, 1989
Pinkerton, CR, Lewis, IJ, Pearson, Adj, Stevens, McG, Barnes, J   +4 more
openaire   +2 more sources

Cisplatin Neuropathy

Neurology, 1995
Hol, EM, Bar, PR, Cavaletti, G, Tredici, G, Windebank, AJ, Gordon, SA, Russell, JW   +6 more
openaire   +1 more source

Cisplatin and myoelectric activity [PDF]

Digestive Diseases and Sciences, 1988
Ivan M. Lang, Ivan M. Lang
openaire   +2 more sources